For patients with multiple myeloma, the use of novel agents in first-line triplet and quadruplet induction regimens -- with or without high-dose therapy and autologous stem cell transplant (ASCT) -- ...

Introduction Multiple myeloma (MM) is a malignancy derived from terminally differentiated plasma cells and has become the second most prevalent hematological cancer (1). Extramedullary disease (EMD) ...